

Precision ADVANCE Events & Expertise

Events

Conferences & Panels

- [The 4th Annual Gene Therapy for Rare Disorders, February 22-25](#)
- [Immuno-Oncology 360°, February 16-18](#)
- [Cell & Gene Meeting on the Med \(ARM\), April 6-9](#)
- [World EPA Congress, April 13-15](#)
- [American Society of Gene & Cell Therapy, May 11 – 14](#)
- [Virtual ISPOR US 2021, May 17-20](#)
- [World Orphan Drug Congress, August 25-27](#)
- [AMCP Cell & Gene Day, September 9](#)
- [STAT Digital Summit, October 14](#)
- [World Orphan Drug Congress EU, November 15-18](#)

Select On-Demand Webinars

- [CAR-T Europe: CTx in Liquid and Solid Tumours With Experts From King's College London](#)
- [Demonstrating the Short and Long Term Value of Gene and Cellular Therapies](#)
- [Gene Therapies in Hemophilia](#)
- [Harnessing CAR-T Therapy for Hematologic Malignancies and Solid Tumors: Experience from City of Hope](#)
- [Wish I Knew Then What I Know Now: How Cell And Gene Therapies Are Reshaping Commercialization Strategies For Advanced Technologies](#)
- [The Great Debate: Internal vs. External Manufacturing for Advanced Therapies](#)

Thought Leadership

- [Why Gene Therapy Lotteries Are Good for Patients, Providers, and Manufacturers, **Informa Connect**](#)
- [CAR-T Therapy and Historical Trends in Effectiveness and Cost-Effectiveness of Oncology Treatments, **Future Medicine**](#)
- [Value of Gene Therapies for Rare \(And Not So Rare\) Diseases, **MedAd News**](#)
- [The Importance of Biomarker Management, **Applied Clinical Trials**](#)
- [Charting A Course Into The Unknown: Manufacturer Considerations In Gene Therapy, **Cell & Gene**](#)
- [Breaking The Bottleneck For Cell And Gene Therapy Studies: Strategies For Creating Clinical Enthusiasm And Selecting Sites, **Cell & Gene**](#)
- [Manufacturing Skills Gap Creates Bottleneck for Cell and Gene Therapy, **BioSpace**](#)
- [Taking On The Talent Crunch In Biopharma, Cell & Gene Manufacturing, **Cell & Gene**](#)
- [How To Calculate Viral Vector Yields: A Critical Component Of The "Make vs Buy" Analysis, **Cell & Gene**](#)

White Papers

- [Advantages of Using POD Cleanroom Technology](#)
- [Delivering on the Promise of Cell Therapy: Challenges and Trends](#)
- [Optimizing Successful Development of Viral Vector Gene Therapies, Gene Therapy Trials, and Companion Diagnostics](#)
- [Perspective on Gene Therapy: Defining and Demonstrating Value to Payers](#)
- [What to Consider When Conducting a “Make vs. Buy” Analysis for a Cell & Gene Therapy Facility](#)
- [Developing Advanced Therapies: Considerations for Internal Versus External Manufacturing](#)

Peer-Reviewed Papers and Posters

- Dean R, Arjunji R, Awano H, Igarash A, Tanaka A, Jensen IS, Cyr PL, Miller B, Maru B, Sproule DM, Feltner, Malone DC, Dabbous O. *Cost-effectiveness of onasemnogene abeparvocec (ZOLGENSMA) for spinal muscular atrophy type 1 against nusinersen in Japan*. ISPOR 25th Annual International Meeting. Orlando FL. 2020.
- Gorovits, B., Fiscella, M., Havert, M. et al. *Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays*. AAPS J 22, 24 (2020).
- Miller B, Jensen IS, Dean R, Cyr PL, Slocomb T, James E, Beggs AH. *Health resource use in patients with x-linked myotubular myopathy (XLMTM): Data from the RECENSUS Study*. ISPOR 25th Annual International Meeting. Orlando FL. 2020.
- Sacks NC, Healey B, Cyr PL, Graham R. *Healthcare resource use and expenditures in patients with X-linked myotubular myopathy (XLMTM)*. ISPOR 25th Annual International Meeting. Orlando FL. 2020.
- Sacks NC, Healey B, Cyr PL, Graham R. *Economic Burden of X-Linked Myotubular Myopathy (XLMTM) By Ventilation Status*. ISPOR 25th Annual International Meeting. Orlando FL. 2020.
- Gorovits, B., Koren, E. *Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics*. BioDrugs 33, 275–284 (2019).
- Malone DC, Dean R, Arjunji R, Jensen IS, Cyr PL, Miller B, Maru B, Sproule D, Feltner DE, Dabbous O. *Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients*. Journal of Market Access & Health Policy. 2019; VOL. 7, 1-13.
- Hathway J, Purdum AG, Lin VW, Cyr PL, Westin J, Jensen IS. *A budget impact model of axicabtagene ciloleucil in a US population of patients with relapsed/refractory large B-Cell Lymphoma RR-LBCL*. European Blood and Marrow Transplantation Meeting, Lisbon Portugal. 2018.
- Jensen IS, Zacherle E, Noone J, Blanchette C, Nichols Kay C. *Estimating the Life-time Indirect Costs of Vision Impairment (VI) in Inherited Retinal Degeneration (IRD): Economic Impact on Education, Government Benefit Programs, Productivity and Tax Loss for Patients and Caregiver Burden*. American Association of Ophthalmology. Chicago IL. 2018.
- Dean R, Jensen IS, Cyr PL, Miller B, Maru B, Sproule DM, Feltner DE, Wiesner T, Malone DC, Bischof M, Toro W, Dabbous O. *An updated cost-utility model for onasemnogene abeparvocec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)*. Journal of Market Access & Health Policy. Online. 2021.

Connect with one of our experts.

Contact us at precisionadvance@precisionmedicinegrp.com.



To learn more about Precision ADVANCE, visit precisionmedicinegrp.com/advance.